Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CCNH | P51946 | 1/20 | 0.33 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14175380 | 0.89 | CDK1 (0.41) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL5083697 | 0.85 | CCNB2 (0.39) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL5086114 | 0.82 | HPRT1 (0.37) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL5083628 | 0.76 | ADORA2A (0.49) | LMNA | |
| SCHEMBL5083570 | 0.73 | CDK1 (0.34) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL14175378 | 0.73 | CCNB2 (0.46) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL14175387 | 0.71 | CCNB2 (0.41) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL14175382 | 0.71 | CDK1 (0.41) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL29259405 | 0.71 | CCNB2 (0.38) | CDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL14175403 | 0.69 | CCNB2 (0.40) | CDK1CCNB2CCNB1CCNB3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | CDK1 704/4885CCNB2 428/4885CCNB1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.